Literature DB >> 24790045

[The development of mucosal vaccine using bacterial function for targeting mucosal tissues].

Hidehiko Suzuki1, Masuo Kondoh, Kiyohito Yagi, Hiroshi Kiyono, Jun Kunisawa.   

Abstract

Most pathogens invade body through the mucosal epithelium, which is a primary target to prevent the infectious diseases. Mucosal vaccine has been considered to be an effective strategy to establish immunosurveillance against pathogens by the induction of antigen-specific immune responses at both mucosal and systemic immune compartments. The development of antigen delivery system and mucosal adjuvants are required for the sufficient induction of protective immunity in the development of mucosal vaccine. In this review, we shed light on the recent advances in the development of antigen delivery system using microbial functions for mucosal vaccines.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24790045     DOI: 10.1248/yakushi.14-00006-3

Source DB:  PubMed          Journal:  Yakugaku Zasshi        ISSN: 0031-6903            Impact factor:   0.302


  7 in total

1.  Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.

Authors:  Rui Tada; Shoko Muto; Tomoko Iwata; Akira Hidaka; Hiroshi Kiyono; Jun Kunisawa; Yukihiko Aramaki
Journal:  BMC Res Notes       Date:  2017-01-26

2.  Chemically Synthesized Alcaligenes Lipid A Shows a Potent and Safe Nasal Vaccine Adjuvant Activity for the Induction of Streptococcus pneumoniae-Specific IgA and Th17 Mediated Protective Immunity.

Authors:  Ken Yoshii; Koji Hosomi; Atsushi Shimoyama; Yunru Wang; Haruki Yamaura; Takahiro Nagatake; Hidehiko Suzuki; Huangwenxian Lan; Hiroshi Kiyono; Koichi Fukase; Jun Kunisawa
Journal:  Microorganisms       Date:  2020-07-23

3.  Polymeric Caffeic Acid Acts as a Nasal Vaccine Formulation against Streptococcus pneumoniae Infections in Mice.

Authors:  Rui Tada; Hidehiko Suzuki; Miki Ogasawara; Daisuke Yamanaka; Yoshiyuki Adachi; Jun Kunisawa; Yoichi Negishi
Journal:  Pharmaceutics       Date:  2021-04-20       Impact factor: 6.321

4.  Enzymatically polymerised polyphenols prepared from various precursors potentiate antigen-specific immune responses in both mucosal and systemic compartments in mice.

Authors:  Rui Tada; Miki Ogasawara; Daisuke Yamanaka; Yasuhiro Sakurai; Yoichi Negishi; Hiroshi Kiyono; Naohito Ohno; Jun Kunisawa; Yukihiko Aramaki
Journal:  PLoS One       Date:  2021-02-08       Impact factor: 3.240

5.  Role of Interleukin-6 in the Antigen-Specific Mucosal Immunoglobulin A Responses Induced by CpG Oligodeoxynucleotide-Loaded Cationic Liposomes.

Authors:  Rui Tada; Emi Honjo; Shoko Muto; Noriko Takayama; Hiroshi Kiyono; Jun Kunisawa; Yoichi Negishi
Journal:  Membranes (Basel)       Date:  2022-06-20

6.  Intranasal administration of cationic liposomes enhanced granulocyte-macrophage colony-stimulating factor expression and this expression is dispensable for mucosal adjuvant activity.

Authors:  Rui Tada; Akira Hidaka; Hiroshi Kiyono; Jun Kunisawa; Yukihiko Aramaki
Journal:  BMC Res Notes       Date:  2018-07-13

7.  Essential Role of Host Double-Stranded DNA Released from Dying Cells by Cationic Liposomes for Mucosal Adjuvanticity.

Authors:  Rui Tada; Akihiro Ohshima; Yuya Tanazawa; Akari Ohmi; Saeko Takahashi; Hiroshi Kiyono; Jun Kunisawa; Yukihiko Aramaki; Yoichi Negishi
Journal:  Vaccines (Basel)       Date:  2019-12-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.